Jennifer R. Molina, Ph.D.
Affiliations: | 2009 | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Molecular Biology, BiochemistryGoogle:
"Jennifer Molina"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Maria-Magdalena Georgescu | grad student | 2009 | The University of Texas Graduate School of Biomedical Sciences at Houston | |
| (NHERF1 recruits the tumor suppressors PTEN and PHLPP to synergistically inhibit the PI-3K pathway.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Gozgit JM, Vasbinder MM, Abo RP, et al. (2021) PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell |
| Schenkel L, Molina J, Swinger K, et al. (2020) Abstract 1038: A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants Cancer Research. 80: 1038-1038 |
| Molina JR, Sun Y, Protopopova M, et al. (2018) An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nature Medicine |
| Marszalek JR, Seth S, Corti D, et al. (2018) Abstract 2856: Targeting OXPHOS with IACS-010759 to eliminate standard of care resistant tumor cells Cancer Research. 78: 2856-2856 |
| Francesco MED, Marszalek JR, McAfoos T, et al. (2018) Abstract 1655: Discovery and development of IACS-010759, a novel inhibitor of Complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors Cancer Research. 78: 1655-1655 |
| Baran N, Han L, Sweeney SR, et al. (2017) Inhibition of Oxphos with Iacs-010759 Depletes AML Leukemia Initiating Cells (LIC) in Vitro and Improves Survival in Pre-Clinical AML Models Blood. 130: 1350-1350 |
| Molina J, Bandi M, Bardenhagen J, et al. (2017) Abstract 4971: IACS-010759, a novel inhibitor of complex I in Phase I clinical development to target OXPHOS dependent tumors Cancer Research. 77: 4971-4971 |
| Baran N, Han L, Herbrich S, et al. (2017) Novel Complex I inhibitor IACS-010759 Targets Leukemia Initiating Cells (LICs) in AML Patients Clinical Lymphoma Myeloma and Leukemia. 17: S297 |
| Jinesh GG, Molina JR, Huang L, et al. (2016) Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discovery. 2: 16003 |
| Molina JR, Protopopova M, Bandi M, et al. (2016) Abstract 335: Title: IACS-010759 is a novel clinical candidate that targets AML cells by inducing a metabolic catastrophe through inhibition of oxidative phosphorylation Cancer Research. 76: 335-335 |